WASHINGTON (Reuters) - A new vaccine to protect women and girls from a sexually transmitted virus that causes cervical cancer comes under scrutiny on Thursday when a U.S. advisory panel considers whether to back approval. The vaccine, made by Merck & Co. Inc., is designed to prevent infection with common types of the human papilloma virus, or HPV, which causes warts and most cervical cancer.
